Ausun Pharm(SH:603229) Xin Lang Cai Jing·2026-01-07 01:31Core Viewpoint - Aoxiang Pharmaceutical experienced a slight decline in stock price and has significant financing activities, indicating a mixed market sentiment towards the company. Group 1: Financial Performance - For the period from January to September 2025, Aoxiang Pharmaceutical reported a revenue of 646 million yuan, representing a year-on-year decrease of 6.40% [2] - The net profit attributable to the parent company for the same period was 207 million yuan, down 9.59% year-on-year [2] Group 2: Shareholder Information - As of September 30, 2025, the number of shareholders in Aoxiang Pharmaceutical increased to 32,000, reflecting a growth of 5.64% compared to the previous period [2] - The average number of circulating shares per shareholder decreased by 5.34% to 25,948 shares [2] Group 3: Financing Activities - On January 6, Aoxiang Pharmaceutical's financing buy-in amounted to 9.57 million yuan, with a net financing buy of 1.04 million yuan [1] - The total financing and securities balance reached 401 million yuan, accounting for 4.81% of the circulating market value, which is above the 80th percentile of the past year [1] - The company had a low short-selling balance of 347,700 yuan, indicating a low level of short interest [1] Group 4: Dividend Distribution - Aoxiang Pharmaceutical has distributed a total of 286 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [3] Group 5: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 5.36 million shares, an increase of 160,600 shares from the previous period [3]